Nirvana Life Sciences: New License For Psychedelics' Speedy Delivery Method
Nirvana Life Sciences: New License For Psychedelics' Speedy Delivery Method
Canada's Nirvana Life Sciences Inc. recently acquired a license for a novel delivery system for its psychedelics-based therapies currently in development.
加拿大的涅槃生命科學公司。最近獲得了一種新型遞送系統的許可證,目前正在開發基於迷幻藥物的療法。
The company, which seeks to develop psychedelic therapeutic medicines including non-addictive chronic pain and relapse-prevention products, added this novel delivery system to its portfolio. The delivery system is destined for active pharmaceutical ingredients (APIs) with high bioavailability and rapid onset.
該公司尋求開發迷幻治療藥物,包括非成癮的慢性疼痛和預防復發產品,將這種新型遞送系統添加到其產品組合中。遞送系統的目的地是生物利用度高、起效快的活性藥物成分(原料藥)。
The system, manufactured for the licensor Hai Beverages Inc., will be used as a formulating agent for both water-soluble and non-water-soluble APIs. Their onset, when taken orally, would be standard twenty to forty-five minutes, yet this method allows the compound to bypass first pass liver metabolism and directly enter the bloodstream with a rapid onset of 5 minutes or less.
為許可方製造的系統海飲料公司,將用作水溶性和非水溶性原料藥的配方助劑。口服時,它們的起效時間是標準的20到45分鐘,但這種方法允許化合物繞過肝臟代謝,直接進入血液,快速起效5分鐘或更短時間。
The growing interest in psychedelics-assisted therapy calls for innovative ways of efficiently delivering the APIs on various psychedelics.
人們對迷幻劑輔助治療的興趣與日俱增,需要創新的方法來有效地為各種迷幻劑提供原料藥。
For instance, MDMA's timing usually brings anxiety to patients, so they would benefit from a system that shortens the time of onset. Or dissociative drugs like ketamine, if a dose could be rendered orally but effectively come on as if injected intramuscularly; the advancement could be revolutionary to the field.
例如,MDMA的時機通常會給患者帶來焦慮,所以他們將受益於一個縮短髮病時間的系統。或者像氯胺酮這樣的解離藥物,如果一劑藥物可以口服,但實際上就像肌肉注射一樣;這一進步可能會對該領域產生革命性影響。
As Nirvana's head of innovation and chief chemist, Robert August, said: "We are very excited to see what new and interesting formulations we can develop with this system in the therapeutic psychedelic sector."
AS涅槃創新主管兼首席化學家羅伯特·奧古斯特説:“我們非常興奮地看到我們可以在治療迷幻領域利用這個系統開發出什麼新的和有趣的配方。”
The company is working with Dr. Nabissi and the ITD Labs team on the mechanism's formulation. They will then move on to utilize their latest in vivo, in vitro and pharmacokinetics and pharmacodynamics study data on psychedelics to continue expanding their portfolio of formulations for use in psychedelic therapeutic medicine.
該公司正在與納比西博士和ITD實驗室團隊關於這個機制的表述。然後,他們將繼續利用他們關於迷幻劑的最新體內、體外和藥代動力學和藥效學研究數據,以繼續擴大他們用於迷幻治療藥物的配方組合。